Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    Have you forgotten your password?
Repository logoRepository logo
  • Communities & Collections
  • All Contents
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Српски
  • Yкраї́нська
  • Log In
    Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Serdaroglu S."

Now showing 1 - 2 of 2
Results Per Page
Sort Options
  • No Thumbnail Available
    Item
    Quality of life, anxiety and depression in patients with androgenetic alopecia
    (Medcom Limited, 2021) Bilaç C.; Öztürkcan S.; Sahin M.T.; Kutlubay Z.; Serdaroglu S.; Yasar A.; Dinç G.
    Background: Androgenetic alopecia (AGA) is a common form of hair loss, which can result in body image disorder and negative social feelings. Aim: The aim of this study was to evaluate the quality of life (QoL) and the risk of anxiety and depression in AGA patients. Method: Sociodemographic data of the patients and clinical severity of the disease were recorded. The QoL score of patient and controls was evaluated with DLQI and SF-36 instruments, their anxiety and depression risks were evaluated with HAD (HAD-A and HAD-D) instruments. Results: Sixty-eight patients with AGA were included in our study. Young male AGA patients' quality of life levels were found to be low according to role limitations due to emotional problems, emotional well-being and emotional scores of SF-36 scale and younger female AGA patients quality of life levels were also found to be low according to role limitations due to emotional problems, and emotional scores of SF-36 scale. The DLQI scores of patients of both sex were found to be sig nificantly higher compared to control group. According to anxiety and depression risk assessment with HAD scale, it was found that 28.6% and 73.5% of patients were prone to suffer from anxiety and depression respectively. Conclusion: Apart from managing alopecia, practitioners should be aware of the possible psychosocial distress of AGA patients and manage accordingly. © 2021 Medcom Limited. All rights reserved.
  • No Thumbnail Available
    Item
    Relationship of psoriatic arthritis with nail and scalp involvement in Turkish psoriasis patients: Multicentered cross-sectional study
    (Lippincott Williams and Wilkins, 2024) Askin O.; Engin B.; Ozdede A.; Kartal S.P.; Ugurlu S.; Akbulut T.O.; Ekinci A.P.; Aydogdu İ.H.; Ozden M.G.; Kok H.; Dogan S.; Ozturkcan S.; Borlu M.; Baskan E.B.; Yilmaz N.; Ak T.; Topkarci Z.; Serdaroglu S.
    Psoriasis is a common multisystem inflammatory disease, and arthritis is an essential component of the disorder, requiring early diagnosis and prompt treatment for successful management. In this study, we aimed to investigate the relationship between nail and scalp involvement and other covariates with psoriatic arthritis (PsA). This cross-sectional study, conducted from June 2021 through December 2021, included 763 patients from 11 different centers in Turkey. The severity of involvement was evaluated using psoriasis area severity index (PASI), nail psoriasis severity index (NAPSI), and psoriasis scalp severity index (PSSI) scores. Predictors for PsA were evaluated using univariate and multivariate logistic regression models. PsA (n = 155, 21.5%) was significantly more common in patients having a family history of psoriasis (43.2% vs 30.9%, P = .004), nail involvement (68.4% vs 52.3%, P < .001), and coexistence of nail and scalp involvement (53.7% vs 39.6%, P = .002). Furthermore, patients with PsA had considerably higher PASI (7 vs 5.6, P = .006), NAPSI (5 vs 2, P < .001), and PSSI scores (7 vs 4, P = .002) and longer disease duration (months) (126 vs 108, P = .009). In multivariate analysis, female gender [OR: 3.01, 95% CI (1.861-4.880), P < .001], nail involvement [OR: 2.06, 95% CI (1.293-3.302), P = .002)], and body mass index (BMI) [OR: 1.06, 95% CI (1.017-1.100), P = .005] were identified as independent predictors for PsA. Female gender, nail involvement, and high BMI are significant predictors for PsA and warrant detailed rheumatological assessment. Notably, being female is the strongest predictor of increased risk of PsA in our survey. Scalp involvement appears not to be associated with PsA. Also, the presence of PsA seems related to a more severe skin involvement phenotype. Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

Manisa Celal Bayar University copyright © 2002-2025 LYRASIS

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback